BCRX - BioCryst Pharmaceuticals, Inc.
| Previous close | 8.39 |
| Open | 8.45 |
| Bid | 8.34 x 1400 |
| Ask | 8.35 x 1400 |
| Day's range | 8.30 - 8.49 |
| 52-week range | 7.20 - 15.43 |
| Volume | |
| Avg. volume | 2,808,263 |
| Market cap | 1.577B |
| Beta (5Y monthly) | 2.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.23 |
| Earnings date | 02 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.15 |
Motley FoolBioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX)Q1 2023 Earnings CallMay 03, 2023, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to the BioCryst Q1 2023 earnings conference call.
Motley FoolWhy BioCryst Pharmaceuticals Stock Is Soaring Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a healthy 14% as of 1:40 p.m. ET Wednesday. Although it missed Wall Street's consensus top-line estimate by $2.6 million for the quarter, investors appear to be more concerned about BioCryst's overall financial health and near-term outlook. BioCryst said that in Q1, the number of U.S. patients taking its oral hereditary angioedema (HAE) drug Orladeyo rose by 46% year over year.
ZacksCollegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksWill BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolWhy Shares of BioCryst Pharmaceuticals Jumped Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were up 12% Wednesday afternoon, a day after the commercial-stage biotech released full-year and fourth-quarter earnings. The stock dropped as much as 17.1% on Tuesday after the earnings report, but Wednesday, it bounced back as much as 14% over the day before. Needham upgraded the stock to "buy" from "hold," adding a $14 price target, and H.C. Wainwright analyst Andrew Fein set a price target of $30 on the stock and reiterated his buy rating.
Motley FoolWhy BioCryst Pharmaceuticals Stock Is Sinking Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are sinking today, down by 17.1% as of 11:09 a.m. ET. The big decline came after the drugmaker announced its fourth-quarter and full-year 2022 results before the market opened. BioCryst reported Q4 revenue of $79.5 million, up from $47.2 million in the prior-year period.
- Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript
Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; and chief R&D officer, Dr. 2022 was another outstanding year for ORLADEYO as we doubled sales in our second full year of launch on top of the fantastic start we had in the first year.
ZacksBioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksWhy Earnings Season Could Be Great for BioCryst (BCRX)
BioCryst (BCRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ZacksEarnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksBioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksWall Street Analysts Predict a 48% Upside in BioCryst (BCRX): Here's What You Should Know
The mean of analysts' price targets for BioCryst (BCRX) points to a 47.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZacksBioCryst (BCRX) Down as it Discontinues Developing PNH Drug
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Motley FoolBioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript
Participating with me today are CEO, Joh Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; and chief R&D officer, Dr. New patient starts are consistent with previous quarters, discontinuations appear to have stabilized, and we are investing more to keep this momentum going.
ZacksBioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksTheravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolGot $3,000? Here Are 2 Stocks That Will Make You Richer
BioCryst Pharmaceuticals and Steris could both deliver outstanding returns for patient shareholders.
ZacksHas Alignment Healthcare (ALHC) Outpaced Other Medical Stocks This Year?
Here is how Alignment Healthcare (ALHC) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Motley FoolBioCryst Pharmaceuticals (BCRX) Q2 2022 Earnings Call Transcript
At this time, [Operator instructions] I will now turn the call over to your host, Mr. John Bluth at BioCryst. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; chief medical officer, Dr.
- Motley Fool
Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
Shares of the rare disease specialist BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a noteworthy 20% on heavy volume at 9:38 a.m. ET Thursday morning. Although the biotech reported encouraging 2022 second-quarter results prior to today's opening bell, the real needle mover here appears to be the news that the Food and Drug Administration (FDA) has lifted the partial clinical hold on BCX9930. BCX9930 is an oral Factor D inhibitor indicated for a rare blood disease known as paroxysmal nocturnal hemoglobinuria (PNH).
ZacksBioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 11.11% and 2.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool
3 Fast-Growing Stocks to Buy Now
It's really exciting to see triple-digit revenue growth. ShockWave Medical (NASDAQ: SWAV) and BioCryst Pharmaceuticals (NASDAQ: BCRX) are blowing the roof off right now, with 194% and 162% sales increases, respectively.
Motley Fool2 Biotech Stocks You'll Regret Not Buying on the Dip
Biotech stocks were among the first group of equities to head southward late last year. The closely watched iShares Biotechnology ETF and SPDR S&P Biotech ETF are up by 2.56% and 7.62%, respectively, since July 1. Which beaten-down biotech stocks might come roaring back in the second half of 2022?
Yahoo Finance VideoMeme stocks: GameStop, AMC decline in intraday trading
Yahoo Finance Live’s Brian Cheung breaks down how meme stocks are performing on Tuesday.
ZacksStrength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?
BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.